Identification of Novel Target for Osteosarcoma by Network Analysis

Li-Qiang Zhi*
Yi-Xin Yang*
Shu-Xin Yao
Zhong Qing
Jian-Bing Ma

* These authors contributed equally to this work

Corresponding Author: Jian-Bing Ma, e-mail: majianbing888@163.com

Source of support: This work was supported by a General Financial Grant from the China Postdoctoral Science Foundation (2017M623215)

Background: Osteosarcoma (OS) is a highly complicated bone cancer involving imbalance of signaling transduction networks in cells. Development of new anti-osteosarcoma drugs is very challenging, mainly due to lack of known key targets.

Material/Method: In this study, we attempted to reveal more promising targets for drug design by “Target-Pathway” network analysis, providing the new therapeutic strategy of osteosarcoma. The potential targets used for the treatment of OS were selected from 4 different sources: DrugBank, TCRD database, dbDEMC database, and recent scientific literature papers. Cytoscape was used for the establishment of the “Target-Pathway” network.

Results: The obtained results suggest that tankyrase 2 (TNKS2) might be a very good potential protein target for the treatment of osteosarcoma. An in vitro MTT assay proved that it is an available option against OS by targeting the TNKS2 protein. Subsequently, cell cycle and apoptosis assay by flow cytometry showed the TNKS2 inhibitor can obviously induce cell cycle arrest, apoptosis, and mitotic cell death.

Conclusions: Tankyrase 2 (TNKS2), a member of the multifunctional poly(ADP-ribose) polymerases (PARPs), could be a very useful protein target for the treatment of osteosarcoma.

MeSH Keywords: Database • Enzyme Inhibitors • MicroRNAs • Osteosarcoma

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/909973
**Background**

Osteosarcoma (OS) frequently occurs in teenagers and young adults and causes 20% of all primary bone cancers [1]. Despite the success of neoadjuvant chemotherapy followed by surgical resection for osteosarcoma, the survival rate of pediatric patients is still low, and their progression-free survival was reported to be about 23 months [2]. Therefore, discovery of potential diagnostic and effective therapeutic targets used for the treatment of OS is an urgent issue for the development of new OS drugs.

There are dozens of antineoplastic drugs being tested in hundreds of clinical trials for the treatment of osteosarcoma retrieved from the clinicaltrials.gov website [3]. Most clinical candidates involve several crucial cell signaling pathways, particularly protein kinase inhibitors [4]. In addition, the drugs that interacted with DNA, referred to as cytotoxic agents or specific ribozyme inhibitors, are also thought to account for a large proportion in these osteosarcoma clinical trials. Thus, we collected a series of antitumor targets obtained from corresponding experimental drugs for the treatment of OS, as well as the potential therapeutic targets of these drugs for the first step in this study.

MicroRNAs (miRNAs) are small noncoding regulatory RNAs 22–25 nucleotides in length, which widely participate in a number of biological processes [5]. The miRNAs dysfunction that ties many pathological conditions together involves obvious change in several biological processes, including cell proliferation, apoptosis, cell cycle, migration, and invasion [6]. Although this imbalance of miRNAs expression level cannot be considered as the primary cause for various diseases, the expression profiles analysis of miRNAs on a genome-wide scale could contribute to the discovery of new targets, especially for complicated tumor diseases. For example, various recently reported miRNAs suppressed OS cell proliferation, cell cycle progression, and apoptosis, such as miR-20a [7], miR-26a [8], miR-100 [4], miR-124 [9], miR-126 [10], miR-195 [11], miR-205 [12], and miR-491 [13]. Based on these findings, we searched for dozens of various potential targets of OS by querying the validated targets from Tarbase [14], a miRNAs target database.

Although many possible targets used for OS therapy had been reported [15] and many bioinformatics databases such as the Target Central Resource Database (TCRD) have been used to uncover possible targets of OS [16], the most promising targets for clinical use remain to be discovered. In the present study, we explored novel effective targets of OS by network analysis focusing on potential targets collected in as many different ways as possible, and subsequently investigated the underlying mechanism by use of MTT assay and flow cytometry.

Our results may lay the foundation for development of new OS drugs.

**Material and Methods**

**Cell culture**

The 4 human OS cell lines – LM7, SaOS-2, U2OS, and MG-63 – were purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China), and cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Beyotime Biotechnology, Shanghai, China). These 4 cancer cell lines were then incubated at 37°C in a humidified atmosphere containing 5% CO₂.

**Network construction**

The potential targets used for the treatment of OS were selected from 4 different sources: (1) The possible targets retrieved from DrugBank [17] by searching for 28 clinical drugs used for OS (Table 1); (2) The possible kinase targets as shown in Table 2 retrieved from the TCRD database [16] (https://phar.os.nih.gov/tdg/index); (3) The possible targets obtained from Tarbase database on the basis of microRNAs involved with OS validated by recent papers (Table 4). In addition, these targets listed above were imported into the Biological Information Annotation Databases for the molecular function and biological process annotation. To facilitate scientific interpretation of complex relationships between OS targets and signaling pathways, network analysis was performed. The “Target-Pathway” network was generated by Cytoscape (http://www.cytoscape.org/) [19], which is an open-source software for visualizing complex networks and integrating these with any type of attribute data.

**The MTT assay**

Compound NVP-TNK5656 was purchased from SelleckChem. The anti-proliferation activities of prepared compounds were evaluated as described in previous reports [20]. The 4 OS cells – LM7, SaOS-2, U2OS, and MG-63 (5000 cells/well) – were seeded in a 96-well plate, and then incubated with compound (0.5 μM) for 0, 12, 24, or 36 h. Subsequently, 10 μL MTT solution (5 mg/mL; Beyotime Institute of Biotechnology, Haimen, China) was added to each well, followed by incubation for another 4 h. After the supernatant was removed, 100 μL dimethyl sulfoxide was added to each well. The absorbance was detected at 570 nm with a microplate reader.
Table 1. The main clinical drugs that exclude cytotoxic agents used for the treatment of osteosarcoma and their important targets at the clinical Phase I, II, III, and IV currently.

| No. | Drugs          | Targets at the DrugBank database | Name                        | Gene      |
|-----|----------------|---------------------------------|-----------------------------|-----------|
| 1   | Zoledronic acid| Farnesyl pyrophosphate synthase | FDPS                        |           |
|     |                | Geranylgeranyl pyrophosphate synthase | GGPS1                      |           |
| 2   | Leucovorin     | Thymidylate synthase           | TYMS                        |           |
| 3   | Afatinib       | Vascular endothelial growth factor receptor-2 | KDR                  |           |
| 4   | Rapamycin      | Mammalian target of rapamycin  | MTOR                        |           |
| 5   | Sorafenib      | Serine/threonine-protein kinase 8-raf | BRAF                      |           |
|     |                | Vascular endothelial growth factor receptor 2 | KDR                  |           |
|     |                | Mast/stem cell growth factor receptor Kit | KIT                    |           |
| 6   | Methotrexate   | Dihydrofolate reductase        | DHFR                        |           |
| 7   | Pembrolizumab  | Programmed cell death protein 1 | PDCD1                       |           |
| 8   | Etoposide      | DNA topoisomerase 2-alpha      | TOP2A                       |           |
| 9   | Avelumab       | programmed death-ligand 1     | PDCD1L1                     |           |
| 10  | Eribulin       | Tubulin beta-1 chain          | TUBB1                       |           |
| 11  | Pazopanib      | Vascular endothelial growth factor receptor 1 | Flt1              |           |
|     |                | Vascular endothelial growth factor receptor 2 | KDR                  |           |
|     |                | Platelet-derived growth factor receptor alpha | PDGFRalpha |           |
|     |                | Platelet-derived growth factor receptor beta | PDGFRbeta |           |
| 12  | Lenvatinib     | Vascular endothelial growth factor receptor 1 | Flt1              |           |
|     |                | Vascular endothelial growth factor receptor 2 | KDR                  |           |
|     |                | Vascular endothelial growth factor receptor 3 | FLT4               |           |
|     |                | Fibroblast growth factor receptor 1 | FGFR1                      |           |
|     |                | Fibroblast growth factor receptor 2 | FGFR2                      |           |
|     |                | Fibroblast growth factor receptor 3 | FGFR3                      |           |
|     |                | Fibroblast growth factor receptor 4 | FGFR4                      |           |
| 13  | Cabozantinib   | Hepatocyte growth factor receptor | MET                        |           |
|     |                | Vascular endothelial growth factor receptor 2 | KDR                  |           |
|     |                | Proto-oncogene tyrosine-protein kinase receptor Ret | RET              |           |
| 14  | Regorafenib    | More than 15 protein kinases   |                             |           |
| 15  | Nivolumab      | Programmed cell death protein 1 | PDCD1                       |           |
| 16  | Paclitaxel     | Apoptosis regulator Bcl-2     | BCL2                        |           |
|     |                | Tubulin beta-1 chain          | TUBB1                       |           |
| 17  | Lexatumumab    | Death receptor 5              | TNFRSF10B                   |           |
| 18  | Irinotecan     | DNA topoisomerase 1           | TOP1                        |           |
Table 1. The main clinical drugs that exclude cytotoxic agents used for the treatment of osteosarcoma and their important targets at the clinical Phase I, II, III, and IV currently.

| No. | Drugs       | Targets at the DrugBank database | Name                 | Gene     |
|-----|-------------|----------------------------------|----------------------|----------|
| 19  | Gefitinib   | Epidermal growth factor receptor | EGFR                 |          |
| 20  | RO4929097   | Gamma secretase                  | APH1A/B              |          |
| 21  | Larotrectinib| Troponymyosin kinase             | Trk                  |          |
| 22  | Iplilimumab | Cytotoxic T-lymphocyte protein 4 | CTLA4                |          |
| 23  | Tanespimycin| Heat shock protein 90            | HSP90                |          |
| 24  | Erlotinib   | Epidermal growth factor receptor | EGFR                 |          |
| 25  | Alvocidib   | Cyclin-dependent kinase          | CDK                  |          |
| 26  | Cixutumumab | Insulin-like growth factor 1 receptor | IGF1R           |          |
| 27  | Romidepsin  | Histone deacetylase 1           | HDAC1                |          |
|     |             | Histone deacetylase 2            | HDAC2                |          |
| 28  | Abemaciclib | Cyclin-dependent kinase 4        | CDK4                 |          |
|     |             | Cyclin-dependent kinase 6        | CDK6                 |          |

* Means too many kinases to list in this table.

Table 2. The main potential kinase targets retrieved from the Target Central Resource Database for the treatment of osteosarcoma at the Tclin* and Tchem** development/druggability levels.

| No. | Name                                                      | Gene |
|-----|-----------------------------------------------------------|------|
| 1   | Cyclin-dependent kinase 11B                               | CDK11B |
| 2   | Serine/threonine-protein kinase PAK 5                     | PAK5 |
| 3   | Dual specificity tyrosine-phosphorylation-regulated kinase 1B | DYRK1B |
| 4   | Casein kinase II subunit alpha*                           | CSNK2A2 |
| 5   | Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | PKMYT1 |
| 6   | Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform | PHKA1 |
| 7   | Cyclin-dependent kinase-like 3                            | CDKL3 |
| 8   | Cyclin-dependent kinase 17                                | CDK17 |
| 9   | Cyclin-dependent kinase-like 1                            | CDKL1 |
| 10  | Serine/threonine-protein kinase Nek5                      | NEK5 |
| 11  | SRSF protein kinase 3                                     | SRPK3 |
| 12  | Serine/threonine-protein kinase RIO1                      | RIOK1 |
| 13  | Phosphorylase b kinase gamma catalytic chain, liver/testis isoform | PHKG2 |
| 14  | Atypical kinase COQ8B, mitochondrial                      | COQ8B |
| 15  | Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform | PHKG1 |
| 16  | Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma    | PIP4K2C |
### Table 2. The main potential kinase targets retrieved from the Target Central Resource Database for the treatment of osteosarcoma at the Tclin* and Tchem** development/druggability levels.

| No. | Name                                | Gene |
|-----|-------------------------------------|------|
| 17  | Dual specificity protein kinase CLK4| CLK4 |
| 18  | Serine/threonine-protein kinase 17A | STK17A |
| 19  | Calcium/calmodulin-dependent protein kinase type 1D | CAMK1D |
| 20  | Cyclin-dependent kinase 14          | CDK14 |
| 21  | Serine/threonine-protein kinase PRP4 homolog | PRPF4B |
| 22  | Microtubule-associated serine/threonine-protein kinase 2 | MAST2 |
| 23  | MAP kinase-interacting serine/threonine-protein kinase 2 | MKNK2 |
| 24  | Serine/threonine-protein kinase tousled-like 2 | TLK2 |
| 25  | Dual specificity protein kinase CLK3 | CLK3 |
| 26  | Dual specificity tyrosine-phosphorylation-regulated kinase 2 | DYRK2 |
| 27  | Thymidine kinase 2, mitochondrial   | TK2  |
| 28  | Serine/threonine-protein kinase Nek7 | NEK7 |
| 29  | Phosphatidylinositol 4-kinase alpha | PI4KA |
| 30  | cAMP-dependent protein kinase catalytic subunit beta | PRKACB |
| 31  | Protein kinase C theta type         | PRKCQ |

* These targets have activities in DrugCentral database (approved drugs) with known mechanism of action; ** these targets have activities in ChEMBL or DrugCentral.

### Table 3. The key microRNAs with downregulated expression in osteosarcoma samples from the dbDEMC 2.0 database.

| No. | microRNAs | Targets form Tarbase (Pred.Score ≥0.9 & Gene name) |
|-----|-----------|----------------------------------------------------|
| 1   | miR-1     | TNKS2, SPRED1, SRSF1                               |
| 2   | miR-126   | BRWD3, JARID2, SCD, Npas2, HIPK2                   |
| 3   | miR-133a  | NUP160, SGPP1, COL8A1, FAM1608B1, CELF1, TSPAN18, MAP3K2 |
| 4   | miR-133b  | RB1CC1, CELF1, FTL, MCL1                           |
| 5   | miR-142-3p| TCEB3, TEX2, KDEL2, IRAK1                          |
| 6   | miR-144   | SNTB2, EIF4G2, ZNF367, ZNF800, CEP350, DCP2, TNKS2 |
| 7   | miR-150   | MTCH2, LDLR, PERP                                  |
| 8   | miR-195   | CCNE1, WEE1, FBXW7, IPOP7, E2F3, SKI, AGO1, SON, CDC27, CDC425E2, NUFIP2 |
| 9   | miR-205-5p| CCN1, CBX1, SNW1                                  |
| 10  | miR-206   | GIA1, TNKS2, SRSF9, MMD, GPD2, EFNB2, SERP1, IFT52, TWF1, ZNF264, POG |
| 11  | miR-223   | PARP1, SCARB1, RASGPR1                            |
| 12  | miR-41    | PFA5                                              |
| 13  | miR-486-5p| ST6GA1NAC6, ZNF367                                |
| 14  | miR-497   | RAF1, RUNX2, IGF1R, MAP2K1                        |
Apoptosis analysis

MG-63 cells were seeded in 12-well plates, at 1×10⁵ cells/well, and incubated for 12 h. Cells were treated with this compound at 4 different concentrations (10, 50, 100, and 200 nM) for 24 h. The cell apoptosis was detected using an Annexin-V-FITC Apoptosis Detection kit (KeyGEN, BioTECH, Nanjing, China) by flow cytometry, according to the manufacturer’s instructions. FlowJo software was used for the data analysis (Leonard Herzenberg, Stanford University, USA). Cells staining negative in the presence of Annexin-V and PI were defined as viable cells.

Cell cycle analysis

MG-63 cells were seeded in 6-well plates (1×10⁶ cells/well) and incubated at 37°C for 12 h. The target cells were treated with the compound (0.5 μM) for 24 h. After treatment, cells were collected and fixed with 75% ethanol at –20°C overnight. In the next step, cells were washed with PBS followed by centrifugation, and incubated with 5 μL (10 mg/mL) RNase and 2.5 μL (5 mg/mL) propidium iodide (Beyotime Institute of Biotechnology, Haimen, China) for 30 min. Flow cytometry analysis was performed using CellQuest software (BD Bioscience, USA) and FlowJo software was used for the data analysis (Leonard Herzenberg, Stanford University, USA).

Statistical analysis

All experiments were performed at least 3 times. Values are expressed as the mean ± standard deviation. Significant differences among the groups were determined by one-way analysis of variance using Origin8.6 (OriginLab Corporation, Northampton, MA, USA).

Table 4. The microRNAs reported for the inhibitory activities against osteosarcoma in these recent papers.

| No. | microRNAs     | Targets form Tarbase (Pred.Score ≥ 0.9 & Gene name)                        |
|-----|---------------|---------------------------------------------------------------------------|
| 1   | miR-20a [7]   | GINM1, RUFY2, C2CD2, TNKS2, PTPN4, SIK1, EFCAB1, RASL11B, ZNF367          |
| 2   | miR-26a [8]   | ZBTB18, TOB1, REEP3, MSMO1, OSBP11, DDX3X, NXPE3, HOXA9, ZFHX4, PDHX, EIF4G2 |
| 3   | miR-100 [4]   | NONE                                                                      |
| 4   | miR-124 [9]   | VAMP3, CD164, RAB10, TARBP1, HIPK3, LAMC1, RRAFD, PTBP1, SLC35F5, QSE1, DCAF16, STK35, CGN, AGO1 |
| 5   | miR-125a [38] | MFHAS1, SEMA4C, RORA, FAM118A, KPNA6, ZC3H7B, CDK16                      |
| 6   | miR-126 [10]  | BRWD3, JARID2, SCD, NPAS2, HIPK2                                         |
| 7   | miR-195 [11]  | CCNE1, WEE1, FBXW7, IPO7, E2F3, SKI, AGO1, SON, CDC27, CDC42SE2, NUMP2   |
| 8   | miR-205 [12]  | CCNI, CBX1, SNW1                                                          |
| 9   | miR-216a [39] | GATAD2B                                                                   |
| 10  | miR-382 [40]  | NONE                                                                      |
| 11  | miR-491 [13]  | GATAD2B, DIRAS1, ANKRD52, IGF2BP1                                         |

Results

Drug-target search

While osteosarcoma has been referred to as an “orphan cancer” with no known driver oncogenes [21], it actually was reported to include many useful biomarkers. In order to detect the potential targets for new drugs, we first focused on the clinically known drugs for OS therapy and sorted out 28 monomers (small molecules and monoclonal antibody, as presented in Table 1), as well as seeking corresponding targets of these drugs by searching in the DrugBank database [17]. Secondly, it is well known that there are hundreds of bioinformatic databases on various areas of molecular biology released in the past 10 years [22], forming the basis of “big data”. Among them, Target Central Resource Database (TCRD, https://pharos.nih.gov/idg/index) is mainly curated interrelated data on unstudied and understudied drug targets. We collected 31 potential OS protein kinase targets (Table 2) by searching the TCRD database, taking into consideration their vital function of signaling pathways. Thirdly, a great many powerful studies indicated that miRNAs can effectively regulate OS progression [23–25], leading to the assumption that they should possess 1 or more common drug targets. Thus, searched for possible OS targets of miRNAs related to OS by querying high degree of confidence (Pred.Score ≥ 0.9) targets in Tarbase [14]. We found 171 OS targets.

Network construction and analysis

The 171 potential OS targets were imported into Database for Annotation, Visualization, and Integrated Discovery (DAVID) for mapping these targets into the KEGG pathway database.
As shown in Figure 1, only a few key cell signaling pathways were manually retained, while there were many mapping items presented in the output of the DAVID website. The obtained results showed that the primary molecular mechanism of clinical drugs in Table 1 were the MAPK signaling pathway and the PI3K-Akt signaling pathway. Most of the targets validated from TCRD are shown in Table 2, but there were still several apparent protein targets such as PRKACB, MKNK2, and PAK5 that are closely involved with the MAPK signaling pathway and the ErbB signaling pathway. In addition, it is obvious that half of these miRNAs can also be mapped into these signaling pathways. Searching for new targets around these classical signaling pathways takes considerable effort, but selecting novel targets seemed more meaningful for the development of anti-OS drugs. A series of studies showing that miRNAs can perturb OS could reveal more potential targets. The localized network at the right part of Figure 1 shows that the 3 targets – TNKS2, ZNF367, and BIF4G2 – are also new possible targets in the further target validation stage.

TNSK2 inhibitor decreases OS cell proliferation

The present study evaluated the anti-proliferative activity effects of TNSK2 inhibitor on 4 OS cells (LM7, SaOS-2, U2OS, and MG-63) using the MTT assay. As shown in Figure 2, the target compound effectively inhibited the proliferation of all the tested OS cells at the concentration of 0.5 μM, and also exhibited more potent inhibition over time. Among them, the inhibitory activity against MG63 cells was most potent.

TNSK2 inhibitor induced G2/M phase arrest, and induced OS cell apoptosis in a dose-dependent manner

The TNSK2 inhibitor obviously induced G2/M phase arrest of MG63 cells at the concentration of 100 nM (Figure 3). It was apparent that the percentage of MG63 cells in the G2/M phase was also markedly increased (62% cells) when compared with the blank control. Figure 4 shows that TNSK2 inhibitor induced MG63 cell apoptosis in a dose-dependent manner. The percentage of apoptotic cells determined by flow cytometry analysis was obviously increased with increasing dose (10, 50, 100,
and 200 nM) of test compound. The apoptosis rate of MG63 osteosarcoma cells was 2.73%, 3.87%, 5.89%, and 6.97%, respectively. Moreover, the early apoptosis rate of MG63 cells was 12.9%, even at the low concentration of NVP-TNKS656 (10 nM, Figure 4A).

Discussion

All the potential targets are presented in detail in Tables 1–4. In order to build the network more conveniently, the 28 drugs in Table 1 were named as “clinical drugs”. For the TCRD targets in Table 2, we attempted to connect them with the supposition “TCRD_Obtained”. The dataset in Tables 3 and 4 could be employed for the establishment of the “miRNA-Targets” network (Figure 1). As mentioned previously, the network of the signaling pathway is a great source of protein targets in OS cells, as well as other common cancer cells such as EGFR [26] located in the ErbB signaling pathway as a tumor marker or valid target used for the treatment of non-small cell lung cancer (NSCLC).

TNSKS2, which is a poly (ADP-ribose) polymerase (PARP) that adds ADP-ribose polymers onto target proteins [20]. In fact, as blockbuster PARP inhibitors such as Olaparib [27], Rucaparib [28], and Niraparib [29] have been approved as novel...
anticancer agents in the last 2 years, the development of PARP inhibitors has been regarded as the new direction of anticancer drugs. Moreover, TNKS2 was closely correlated with the Wnt/β-catenin pathway, and the inhibition of TNKS2 can overcome resistance to PI3K/AKT inhibitors in cancer therapy [30]. However, there are only a few TNKS2 inhibitors reported to be in the preclinical phase so far. Based on the information above, we surmise that TNKS2 or function-similar proteins might be regarded as a class of novel targets used for the treatment of OS. In this next section, we demonstrate the effectiveness for the inhibition of TNKS2 by preliminary biological assay.

Compound NVP-TNKS656 (Figure 5) was reported to be a highly potent and selective tankyrase inhibitor with the IC₅₀ value of 6 nM against Tankyrase 2 (TNKS2). Tankyrase 2 is regarded

Figure 4. MG-63 cells treated with different concentrations of compound NVP-TNKS656 for 48 h were collected and cell apoptosis was analyzed by flow cytometry. (A) 10 nM; (B) 50 nM; (C) 100 nM; (D) 200 nM.

Figure 5. The chemical structure of NVP-TNKS656 as highly selective tankyrase 2 (TNKS2) inhibitor.
as a key druggable node in the Wnt pathway involved with carcinogenesis, and the 4-methoxybenzoyl-piperidone moiety of this compound is responsible for the inhibition of TNKS2. Actually, the idea of tankyrases as drug targets was put forward as early as 2013 [31], and most studies of tankyrase inhibitors [32-34] have proved them to be effective for specific cancers, possibly including OS. The MTT assay used in this study to a certain extent verified the potential of TNKS2 inhibitor, at least at the OS cell level.

In order to further investigate OS cell suppression by tankyrase inhibition, compound NVP-TNKS656 was chosen for further cell cycle and induced apoptosis assay. The G2/M checkpoint prevents cells from entering mitosis when unrepaired DNA damage was generated in cells [35]. Consistent with previous studies, several papers [30,36,37] on TNSK inhibitors reported that downregulation of the cell cycle regulator Cyclin D1 could explain the G2/M cell cycle, particular the “IWR-1” just published in the Cancer Letters journal [30]. Additionally, we also performed a cell apoptosis experiment to investigate whether the inhibitory activity of NVP-TNKS656 against MG63 cells was related to cell apoptosis. These 2 results provide further evidence that TNSK2 inhibitors have potential for the treatment of OS, and TNSK2 might be a promising target for the design of novel OS drugs.

References:

1. Luetke A, Meyers PA, Lewis J, Juergens H: Osteosarcoma treatment – Where do we stand? A state of the art review. Cancer Treat Rev, 2014; 40: 523–32
2. Fagioli F, Aglietta M, Tienghi A et al: High-dose chemotherapy in the treatment of relapsed osteosarcoma: An Italian sarcoma group study. J Clin Oncol, 2002; 20: 2150–56
3. https://clinicaltrials.gov/
4. Janne PA, Gray N, Settleman J: Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov, 2009; 8: 709–23
5. Ambros V: The functions of animal microRNAs. Nature, 2004; 431: 350–55
6. Yang Y, Huang G, Zhou Z et al: miR-20a regulates fas expression in osteosarcoma cells. Cell Physiol Biochem, 2018; 45: 1410–22
7. Yates LA, Norbury CI, Gilbert RJ: The long and short of microRNA. Cell, 2013; 153: 516–19
8. Wang L, Shan M, Liu Y et al: miR-205 suppresses the proliferative and migratory capacity of human osteosarcoma Mg-63 cells by targeting VEGFA. FEBS J, 2018; 285(7): 1359–71
9. Wang SN, Luo S, Liu C et al: mir-491 inhibits osteosarcoma lung metastasis and chemoresistance by targeting alphab-crystallin. Mol Ther, 2017; 25: 2140–49
10. Jiang R, Zhang C, Liu G et al: ~im-26a-2* inhibits osteosarcoma cell proliferation, invasion, and EMT in osteosarcoma by targeting ZEB1. J Cell Biochem, 2017; 118: 3765–74
11. Cai H, Hao H, Tang J, Wu H: Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma. J Surg Res, 2015; 194: 505–10
12. Wang L, Shang M, Liu Y et al: mir-205 suppresses the proliferative and migratory capacity of human osteosarcoma Mg-63 cells by targeting VEGFA. Oncotarget, 2015; 8: 2635–42
13. Wang SN, Luo S, Liu C et al: mir-491 inhibits osteosarcoma lung metastasis and chemoresistance by targeting alphab-crystallin. Mol Ther, 2017; 25: 2140–49
14. Vlahos IS, Paraskevopoulou MD, Karagkouni D et al: DIANA-TarBase v7.0: Indexing more than half a million experimentally supported miRNA-mRNA interactions. Nucleic Acids Res, 2015; 43: D153–59
15. Nomlos HM, Meza-Zepeda J, Baney T et al: Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One, 2012; 7: e48086
16. Nguyen DT, Mathias S, Bologa C et al: Pharos: Collating protein information to shed light on the druggable genome. Nucleic Acids Res, 2017; 45: D995–1002
17. Wishart DS, Knox C, Guo AC et al: DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res, 2008; 36: D901–6
18. Yang Z, Wu L, Wang A et al: dbDEM C 2.0: Updated database of differentially expressed miRNAs in human cancers. Nucleic Acids Res, 2017; 45: D812–18
19. Shannon P, Markiel A, Ozier O et al: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 2003; 13: 2498–504
20. Ruhlitz MD, Cheung AK, Kirby CA et al: Identification of NVP-TNKS656: The use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. J Med Chem, 2013; 56: 6495–511
21. Moriarity BS, Otto GM, Rahrmann EP et al: A sleeping beauty forward gene therapy vector for integrated models of biomolecular interaction networks. Genome Res, 2003; 13: 2498–504
22. Shultz MD, Cheung AK, Kirby CA et al: Identification of NVP-TNKS656: The use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. J Med Chem, 2013; 56: 6495–511
23. Moriarity BS, Otto GM, Rahrmann EP et al: A sleeping beauty forward gene therapy vector for integrated models of biomolecular interaction networks. Genome Res, 2003; 13: 2498–504
24. Galperin MI, Fernandez-Suarez XM, Rigden DJ: The 24th annual Nucleic Acids Research database issue: A look back and upcoming changes. Nucleic Acids Res, 2015; 43: D995–1002
25. Pal BL, Tong ZW, Wu L et al: Effects of MicroRNA-206 on osteosarcoma cell proliferation, apoptosis, migration and invasion by targeting ANXA2 through the AKT signaling pathway. Cell Physiol Biochem, 2018; 45: 1410–22

Conclusions

Osteosarcoma (OS) is one of the most common human cancers, but there is no clear and effective antitumor target, even for those known clinical candidates used for the treatment of OS, which is very challenging for the development of anti-osteosarcoma drugs. In the present study, we attempted to find more promising targets that might be used for OS therapy by construction and analysis of the “Target-Pathway” network. The obtained results show that tankyrase 2 (TNKS2), a multifunctional poly (ADP-ribose) polymerase (PARP), might be a very potential protein target for the treatment of osteosarcoma. An in vitro MTT assay proved that it is an available option against OS by targeting the TNKS2 protein. Subsequently, cell cycle and apoptosis assay by flow cytometry showed the TNKS2 inhibitor can obviously induce cell cycle arrest, apoptosis, and mitotic cell death. The present study shows a new direction for the development of anti-osteosarcoma drugs and provides a combined medication scheme for the treatment of OS.
26. Paez JG, Janne PA, Lee JC et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science, 2004; 304: 1497–500
27. Feiersinger GE, Trattnig K, Leitner PD et al: Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells. Mol Oncol, 2018; 12(4): 561–76
28. Moore DC, Ringley JT, Patel J: Rucaparib: A Poly(ADP-Ribose) polymerase inhibitor for BRCA-mutated relapsed ovarian cancer. J Pharm Pract, 2017; 1: 897190017743131
29. Moore KN, Mirza MR, Matulonis UA: The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol, 2018;1 49(1): 214–20
30. Martins-Neves SR, Paiva-Oliveira DI, Fontes-Ribeiro C et al: IWR-1, a tankyrase inhibitor, attenuates Wnt/beta-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft. Cancer Lett, 2018; 414: 1–15
31. Lehtio L, Chi NW, Krauss S: Tankyrases as drug targets. FEBS J, 2013; 280: 3576–93
32. Narwal M, Venkannagari H, Lehtio L: Structural basis of selective inhibition of human tankyrases. J Med Chem, 2012; 55: 1360–67
33. Bregman H, Gunaydin H, Gu Y et al: Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. J Med Chem, 2013; 56: 1341–45
34. Bregman H, Chakka N, Guzman-Perez A et al: Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. J Med Chem, 2013; 56: 4320–42
35. Asalathamby A, Hu B, Chen DJ: Unrepaired clustered DNA lesions induce chromosome breakage in human cells. Proc Natl Acad Sci USA, 2011; 108: 8293–98
36. James RG, Davidson KC, Bosch KA et al: WIKI4, a novel inhibitor of tankyrase and Wnt/ss-catenin signaling. PLoS One, 2012; 7: e50457
37. Nathubhai A, Wood PJ, Lloyd MD et al: Design and discovery of 2-aryquinazolin-4-ones as potent and selective inhibitors of tankyrases. ACS Med Chem Lett, 2013; 4: 1173–77
38. Waresijiang N, Sun J, Abuладaini R et al: The downregulation of miR-125a-5p functions as a tumor suppressor by directly targeting MMP-11 in osteosarcoma. Mol Med Rep, 2016; 13(6): 4859–64
39. Ji Q, Xu X, Li L et al: mir-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14. Cell Death Dis, 2017; 8: e3103
40. Xu M, Jin H, Xu CX et al: miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma, Oncotarget, 2014; 5: 9472